I believe TOI is on the verge of profitability and has a solid growth trajectory, making it a worthwhile long-term investment. With increasing revenue and minimal dilution, I see great potential for appreciation, expecting the price to reach between $4 to $6 in the coming months.

I'm really optimistic about TOI because they're making solid moves in the cancer treatment space. With rising revenue from their dispensaries and new contracts, this stock seems poised for significant growth over the next year, especially after breaking past that key 50-day moving average.